What is Mass General Brigham investing in? 21 companies in the health system’s portfolio

Boston-based Mass General Brigham has a large venture capital arm, Mass General Brigham Ventures, and has made some notable investments in the life sciences, biotech, medtech and digital health spaces.

Advertisement
Noah Schwartz

Here are 21 companies in Mass General’s portfolio:

 

  1. Abscuro
  2. Affinia Therapeutics
  3. Amolyt Pharma
  4. Claris Bio
  5. FireCyte Therapeutics
  6. Garuda Therapeutics
  7. InStride Health
  8. Lyndra Therapeutics
  9. Mediar Therapeutics
  10. Nocion Therapeutics
  11. Paros Bio
  12. Photys
  13. Pykus
  14. QurAlis
  15. Rippl Care
  16. ROME Therapeutics
  17. Scorpion Therapeutics
  18. SeQure Dx
  19. SwanBio Therapeutics
  20. Walden Biosciences
  21. Ziel Bio

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

From hidden cost center to strategic asset: Rethinking language services 

Recommended Live Webinar on Jun 23, 2026 1:00 PM - 2:00 PM CDT

Advertisement

Next Up in Innovation

Advertisement

Comments are closed.